← Leaderboards
Daniel J Lerner
Senseion Therapeutics, Inc.
$4,488,496
Attributed
$6,640,902
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.1M · FY2020–25$2.5M$1.9M$1.3M$625K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,640,902 · 3
By mechanism
R44$6,640,902 · 3
Top collaborators
- Jaehyung Cho3 shared
- Rajan Sah2 shared
Others in their field
Other Emerging Leaders on “Pharmacologic Substance”
- Susan M Landau · University Of California Berkeley$47,252,026
- Gary Fanger · Rise Therapeutics, Llc$20,558,417
- Alan D. Palkowitz · Indiana University Indianapolis$17,630,798
- Caroline Sigman · Ccs Associates, Inc.$13,846,650
- Vera Hoffman · Reveal Pharma$12,527,604
- Richard Scranton · Lyndra Therapeutics, Inc.$12,106,230
Research focus
Pharmacologic SubstanceProteinsLeucine-Rich RepeatPharmaceutical PreparationsNon-Insulin-Dependent Diabetes MellitusPre-ClinicalIn VitroLead SeriesMultiple Drug UseInvestigational New Drug ApplicationLeadIon ChannelOralDiabetic MouseDoseComplexEnsureEfficacy StudyHeadBlood Glucose RegulationInvestigational DrugsClinical ResearchIn VivoResponse
Grant awards (8)
Targeting LRRC8 signaling to prevent & treat arterial thrombosis in type 2 diabetes$1,015,058
R44 · FY2025 · HL · contact PI
Targeting LRRC8 signaling to prevent & treat arterial thrombosis in type 2 diabetes$982,162
R44 · FY2024 · HL · contact PI
Targeting LRRC8 signaling to prevent & treat arterial thrombosis in type 2 diabetes$323,485
R44 · FY2023 · HL · contact PI
Optimizing SWELL1 modulators to treat non-alcoholic steatohepatitis$1,089,280
R44 · FY2022 · DK · contact PI
Targeting SWELL1 Signaling to Treat Obesity-Induced Type 2 Diabetes$990,929
R44 · FY2022 · DK · contact PI
Targeting SWELL1 Signaling to Treat Obesity-Induced Type 2 Diabetes$993,178
R44 · FY2021 · DK · contact PI
Optimizing SWELL1 modulators to treat non-alcoholic steatohepatitis$945,785
R44 · FY2021 · DK · contact PI
Optimizing SWELL1 modulators to treat non-alcoholic steatohepatitis$301,025
R44 · FY2020 · DK · contact PI